Maria Marzilli

EVP, Corporate Strategy & Program Operations at Q32 Bio

Maria Marzilli has over 15 years of industry experience across strategy, corporate development, and program and alliance management. Maria joined Q32 Bio from Agios Pharmaceuticals, where she was responsible for Portfolio Strategy and Alliance Management. In that role, she led cross-functional teams tasked with driving portfolio investment decisions and key assessments to inform the company’s overall strategy, business development activities and geographic footprint. She also managed the metabolic immuno-oncology partnership with Celgene, ensuring alignment on strategic and operational goals and priorities. Prior to Agios, Maria held roles of increasing responsibility at Biogen, beginning in Corporate Strategy and supporting the refinement and implementation of the company’s vision, and then moving to Global Market Access, where she helped support pricing and strategy decisions for portfolio programs as well as build out a world class Market Access team. Earlier in her career, she held roles at both Genzyme Corporation and Decision Resources. Maria received her B.A. in Biology from Harvard University and an M.P.H. in Health Services from the Boston University School of Public Health.


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Q32 Bio

1 followers

Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases.


Industries

Employees

11-50

Links